FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2896812857> ?p ?o ?g. }

• W2896812857 abstract "Background Tofacitinib is an oral Janus kinase inhibitor for the treatment of psoriatic arthritis (PsA). Objectives To report the safety, tolerability and efficacy of tofacitinib in patients (pts) with active PsA from an ongoing, open-label, long-term extension (LTE) study (OPAL Balance, NCT01976364; November 2017 data-cut; database not locked). Methods Eligible pts from 2 Phase (P)3 tofacitinib PsA studies (OPAL Broaden, NCT01877668; OPAL Beyond, NCT01882439) entered a 3 year LTE ≤3 months after completing the P3 study or discontinuing for reasons unrelated to study drug. Pts received tofacitinib 5 mg BID to Month (M)1, after which dose adjustments between 5 and 10 mg BID were permitted to improve efficacy, or for safety reasons. Pts receiving a csDMARD at P3 study entry continued the same csDMARD in the LTE. Primary endpoints were incidence and severity of adverse events (AEs) and changes from baseline (Δ) in laboratory values. Safety data are reported up to M36. Efficacy was evaluated up to M30 (when n>50) as a secondary endpoint. Results 686 pts were treated in OPAL Balance; 468 (68.2%) remained in the study at data cut-off. Mean (range) LTE tofacitinib exposure was 614 (1–1032) days. On Day 1, 675 pts (98.4%) received a csDMARD, which was discontinued in 86 pts (12.7%). To M36, 2189 AEs were reported in 546 pts (79.6%), 95 pts (13.8%) had serious AEs and 59 pts (8.6%) discontinued due to AEs. Serious infections occurred in 12 pts (1.7%), herpes zoster (HZ) in 20 pts (2.9%; 1 serious event), major adverse cardiovascular events in 5 pts (0.7%), malignancies in 24 pts (3.5%; including 12 pts with NMSC) and uveitis in 2 pts (0.3%). No AEs of gastrointestinal perforation or inflammatory bowel disease were reported. There were 5 deaths (not attributed to treatment, as assessed by the investigator) due to metastatic pancreatic carcinoma, acute cardiac failure/hypertensive heart disease, chronic obstructive pulmonary disease, pulmonary embolism and cardiovascular insufficiency. Four AEs of latent tuberculosis were reported in pts whose previously negative QuantiFERON response became positive. ALT was elevated ≥3 x ULN in 27 pts (4.0%), and AST≥3 x ULN in 15 pts (2.2%). Changes in laboratory values observed in P3 studies were generally stable in the LTE, except for a modest decrease in absolute lymphocyte count over time. Eight pts (1.2%) discontinued (protocol-mandated) due to laboratory value changes. ACR responses, ΔHAQ-DI, PASI75 response, ΔLeeds Enthesitis Index, ΔDactylitis Severity Score and ΔPain were maintained up to M30. Conclusions Over 36 months in the LTE, the safety profile of tofacitinib in active PsA pts was generally similar to that of the P3 studies. No new safety risks were identified. Efficacy across various PsA disease domains was maintained over time. Acknowledgements Study sponsored by Pfizer Inc. Medical writing support was provided by A MacLachlan of CMC and funded by Pfizer Inc. Disclosure of Interest P. Nash Grant/research support from: AbbVie, Bristol-Myers Squibb, Eli Lilly, Janssen, Novartis, Pfizer Inc, Roche, Sanofi, UCB, Consultant for: AbbVie, Bristol-Myers Squibb, Eli Lilly, Janssen, Novartis, Pfizer Inc, Roche, Sanofi, UCB, Speakers bureau: AbbVie, Bristol-Myers Squibb, Eli Lilly, Janssen, Novartis, Pfizer Inc, Roche, Sanofi, UCB, L. Coates Grant/research support from: AbbVie, Janssen, Consultant for: AbbVie, Amgen, Bristol-Myers Squibb, Celgene, Janssen, Eli Lilly, MSD, Novartis, Pfizer Inc, Sun Pharma, UCB, A. Kivitz Consultant for: AbbVie, Celgene, Genentech, Genzyme, Janssen, Merck, Novartis, Pfizer Inc, Sanofi, UCB, Speakers bureau: AbbVie, Celgene, Genentech, Genzyme, Janssen, Merck, Novartis, Pfizer Inc, Sanofi, UCB, P. Mease Grant/research support from: AbbVie, Amgen, Bristol-Myers Squibb, Celgene, Janssen, Eli Lilly, Novartis, Pfizer Inc, Sun, UCB, Consultant for: AbbVie, Amgen, Bristol-Myers Squibb, Celgene, Janssen, Eli Lilly, Novartis, Pfizer Inc, Sun, UCB, Speakers bureau: AbbVie, Amgen, Bristol-Myers Squibb, Celgene, Genentech, Janssen, Novartis, Pfizer Inc, UCB, D. Gladman Grant/research support from: AbbVie, Amgen, Bristol-Myers Squibb, Celgene, Eli Lilly, Janssen, Novartis, Pfizer Inc, UCB, Consultant for: AbbVie, Amgen, Bristol-Myers Squibb, Celgene, Eli Lilly, Janssen, Novartis, Pfizer Inc, UCB, J. Covarrubias-Cobos Grant/research support from: Bristol-Myers Squibb, Eli Lilly, Janssen, Pfizer Inc, D. Fleishaker Shareholder of: Pfizer Inc, Employee of: Pfizer Inc, C. Wang Shareholder of: Pfizer Inc, Employee of: Pfizer Inc, E. Kudlacz Shareholder of: Pfizer Inc, Employee of: Pfizer Inc, S. Menon Shareholder of: Pfizer Inc, Employee of: Pfizer Inc, L. Fallon Shareholder of: Pfizer Inc, Employee of: Pfizer Inc, T. Hendrikx Shareholder of: Pfizer Inc, Employee of: Pfizer Inc, K. Kanik Shareholder of: Pfizer Inc, Employee of: Pfizer Inc" @default.
• W2896812857 created "2018-10-26" @default.
• W2896812857 creator A5000747220 @default.
• W2896812857 creator A5014612292 @default.
• W2896812857 creator A5022208894 @default.
• W2896812857 creator A5027092636 @default.
• W2896812857 creator A5034581240 @default.
• W2896812857 creator A5046562616 @default.
• W2896812857 creator A5048376276 @default.
• W2896812857 creator A5049489990 @default.
• W2896812857 creator A5081778211 @default.
• W2896812857 creator A5083491872 @default.
• W2896812857 creator A5084902943 @default.
• W2896812857 creator A5085522760 @default.
• W2896812857 creator A5090182951 @default.
• W2896812857 date "2018-06-01" @default.
• W2896812857 modified "2023-09-22" @default.
• W2896812857 title "SAT0293 Safety and efficacy of tofacitinib, an oral janus kinase inhibitor, up to 36 months in patients with active psoriatic arthritis: data from the third interim analysis of opal balance, an open-label, long-term extension study" @default.
• W2896812857 doi "https://doi.org/10.1136/annrheumdis-2018-eular.3115" @default.
• W2896812857 hasPublicationYear "2018" @default.
• W2896812857 type Work @default.
• W2896812857 sameAs 2896812857 @default.
• W2896812857 citedByCount "4" @default.
• W2896812857 countsByYear W28968128572020 @default.
• W2896812857 countsByYear W28968128572021 @default.
• W2896812857 crossrefType "proceedings-article" @default.
• W2896812857 hasAuthorship W2896812857A5000747220 @default.
• W2896812857 hasAuthorship W2896812857A5014612292 @default.
• W2896812857 hasAuthorship W2896812857A5022208894 @default.
• W2896812857 hasAuthorship W2896812857A5027092636 @default.
• W2896812857 hasAuthorship W2896812857A5034581240 @default.
• W2896812857 hasAuthorship W2896812857A5046562616 @default.
• W2896812857 hasAuthorship W2896812857A5048376276 @default.
• W2896812857 hasAuthorship W2896812857A5049489990 @default.
• W2896812857 hasAuthorship W2896812857A5081778211 @default.
• W2896812857 hasAuthorship W2896812857A5083491872 @default.
• W2896812857 hasAuthorship W2896812857A5084902943 @default.
• W2896812857 hasAuthorship W2896812857A5085522760 @default.
• W2896812857 hasAuthorship W2896812857A5090182951 @default.
• W2896812857 hasBestOaLocation W28968128571 @default.
• W2896812857 hasConcept C126322002 @default.
• W2896812857 hasConcept C141071460 @default.
• W2896812857 hasConcept C168563851 @default.
• W2896812857 hasConcept C197934379 @default.
• W2896812857 hasConcept C203092338 @default.
• W2896812857 hasConcept C2776233030 @default.
• W2896812857 hasConcept C2776260265 @default.
• W2896812857 hasConcept C2777077863 @default.
• W2896812857 hasConcept C2777575956 @default.
• W2896812857 hasConcept C2778375690 @default.
• W2896812857 hasConcept C2778715236 @default.
• W2896812857 hasConcept C2778886723 @default.
• W2896812857 hasConcept C61943457 @default.
• W2896812857 hasConcept C71924100 @default.
• W2896812857 hasConcept C90924648 @default.
• W2896812857 hasConceptScore W2896812857C126322002 @default.
• W2896812857 hasConceptScore W2896812857C141071460 @default.
• W2896812857 hasConceptScore W2896812857C168563851 @default.
• W2896812857 hasConceptScore W2896812857C197934379 @default.
• W2896812857 hasConceptScore W2896812857C203092338 @default.
• W2896812857 hasConceptScore W2896812857C2776233030 @default.
• W2896812857 hasConceptScore W2896812857C2776260265 @default.
• W2896812857 hasConceptScore W2896812857C2777077863 @default.
• W2896812857 hasConceptScore W2896812857C2777575956 @default.
• W2896812857 hasConceptScore W2896812857C2778375690 @default.
• W2896812857 hasConceptScore W2896812857C2778715236 @default.
• W2896812857 hasConceptScore W2896812857C2778886723 @default.
• W2896812857 hasConceptScore W2896812857C61943457 @default.
• W2896812857 hasConceptScore W2896812857C71924100 @default.
• W2896812857 hasConceptScore W2896812857C90924648 @default.
• W2896812857 hasLocation W28968128571 @default.
• W2896812857 hasOpenAccess W2896812857 @default.
• W2896812857 hasPrimaryLocation W28968128571 @default.
• W2896812857 hasRelatedWork W2312580319 @default.
• W2896812857 hasRelatedWork W2737739855 @default.
• W2896812857 hasRelatedWork W2749276380 @default.
• W2896812857 hasRelatedWork W2751178115 @default.
• W2896812857 hasRelatedWork W2754241130 @default.
• W2896812857 hasRelatedWork W2755195810 @default.
• W2896812857 hasRelatedWork W2755836038 @default.
• W2896812857 hasRelatedWork W2766717228 @default.
• W2896812857 hasRelatedWork W2766846920 @default.
• W2896812857 hasRelatedWork W2808240072 @default.
• W2896812857 hasRelatedWork W2901200582 @default.
• W2896812857 hasRelatedWork W2910355860 @default.
• W2896812857 hasRelatedWork W2910517343 @default.
• W2896812857 hasRelatedWork W2950880342 @default.
• W2896812857 hasRelatedWork W2952717710 @default.
• W2896812857 hasRelatedWork W3033095461 @default.
• W2896812857 hasRelatedWork W3034117249 @default.
• W2896812857 hasRelatedWork W3045428151 @default.
• W2896812857 hasRelatedWork W3095584460 @default.
• W2896812857 hasRelatedWork W3123452764 @default.
• W2896812857 isParatext "false" @default.
• W2896812857 isRetracted "false" @default.
• W2896812857 magId "2896812857" @default.
• W2896812857 workType "article" @default.